MedPath

Shin Poog Pharmaceutical Co., Ltd.

Ownership
Private
Employees
-
Market Cap
-
Website

Efficacy and Safety for Medicurtain® in Prevention of Adhesion After Endoscopic Sinus Surgery (Pivotal Study)

Not Applicable
Completed
Conditions
Tissue Adhesion, Surgery-Induced
Sinusitis
First Posted Date
2021-09-20
Last Posted Date
2021-09-20
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
77
Registration Number
NCT05049434
Locations
🇰🇷

Korea University Guro Hospital, Seoul, Korea, Republic of

Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008

Phase 1
Completed
Conditions
Acute Coronary Syndrome
Stroke
Interventions
Drug: SP-8008 Prototype Capsule A
Drug: SP-8008 Prototype Capsule B
Drug: Placebo
First Posted Date
2021-02-25
Last Posted Date
2021-02-25
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
48
Registration Number
NCT04770194
Locations
🇬🇧

Quotient Sciences, Nottingham, Nottinghamshire, United Kingdom

The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients

Phase 2
Conditions
Covid19
Interventions
Drug: Artecom® (pyronaridine-artesunate)
Drug: Placebo
First Posted Date
2021-01-08
Last Posted Date
2021-09-30
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
402
Registration Number
NCT04701606
Locations
🇵🇭

De La Salle University Medical Center, Dasmariñas, Gov, D. Mangubat St, 4114 Cavite, Philippines

🇵🇭

The Medical City, Pasig City, Ortigas Avenue, Barangay Ugong, Metro Manila, Philippines

🇵🇭

Lung Center of the Philippines, Quezon City, Quezon Avenue, Quezon City, 1100 Philippines, Philippines

and more 1 locations

Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)

Not Applicable
Completed
Conditions
Lumbosacral Intervertebral Disc Disorders
Tissue Adhesion, Surgery-Induced
Intervertebral Disc Disorder
Thoracic Intervertebral Disc Disorders
Thoracolumbar Intervertebral Disc Disorders
First Posted Date
2020-12-29
Last Posted Date
2021-09-29
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
87
Registration Number
NCT04688281
Locations
🇰🇷

Samsung Medical Center, Seoul, Gangnam-gu, Ilwon-dong 50, Korea, Republic of

The Efficacy and Safety of Medicurtain® in Patients With Total Laparoscopic Hysterectomy (Pivotal Study)

Not Applicable
Completed
Conditions
Tissue Adhesion, Surgery-Induced
Laparoscopy
Leiomyoma of the Uterine Body
First Posted Date
2020-12-17
Last Posted Date
2021-09-29
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
107
Registration Number
NCT04672421
Locations
🇰🇷

Asan Medical Center, Seoul, Seoul Asan Medical Center Gil, Songpa-gu, Korea, Republic of

The Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy (Pivotal Study)

Not Applicable
Completed
Conditions
Intrauterine Synechiae
Tissue Adhesion, Surgery-Induced
First Posted Date
2020-11-20
Last Posted Date
2021-09-29
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
223
Registration Number
NCT04638855
Locations
🇰🇷

Gangnam Severance Hospital, Seoul, Korea, Republic of

COVID-19 Treatment in South Africa

Phase 2
Completed
Conditions
COVID-19
Interventions
Other: Standard of care (Paracetamol)
Drug: Artesunate-amodiaquine
Drug: Pyronaridine-artesunate
Drug: Sofosbuvir/daclatasvir
First Posted Date
2020-08-31
Last Posted Date
2021-09-20
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
192
Registration Number
NCT04532931
Locations
🇿🇦

Ezintsha, Wits Reproductive Health & HIV Institute University of the Witwatersrand, Johannesburg, South Africa

Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

Phase 2
Completed
Conditions
Ischemic Stroke
Interventions
Drug: Placebo
First Posted Date
2020-07-21
Last Posted Date
2023-03-08
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
178
Registration Number
NCT04479449
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Phase 2
Completed
Conditions
COVID-19
Interventions
Drug: Pyronaridine-Artesunate
Drug: Placebo
First Posted Date
2020-07-17
Last Posted Date
2021-06-01
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
113
Registration Number
NCT04475107
Locations
🇰🇷

Korea University Ansan Hospital, Ansan, Korea, Republic of

🇰🇷

Chungnam national University Hospital, Daejeon, Korea, Republic of

🇰🇷

Inha University Hospital, Incheon, Korea, Republic of

and more 10 locations

Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections

Phase 2
Conditions
Malaria,Falciparum
First Posted Date
2019-01-24
Last Posted Date
2019-09-30
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
300
Registration Number
NCT03814616
Locations
🇬🇲

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine,, Fajara,, Banjul,, Gambia

🇿🇲

Tropical Diseases Research Centre, Ndola, Zambia

© Copyright 2025. All Rights Reserved by MedPath